GlassScriptPhysician profile
Heidi A Gallo
NPI 1104807189
$15,111.88
in general payments reported to CMS, 2019-2025
35 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,918 · 2022: $5,787 · 2023: $2,621 · 2024: $3,162 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,358 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,357.65 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,297.86 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $3,207.99 | 2021-2025 | Fasenra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,739.69 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $1,022.52 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $927.92 | 2021 | |
| Novo Nordisk INC | $779.10 | 2021-2024 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $378.19 | 2024 | Voquezna |
| Amgen INC. | $352.62 | 2021-2023 | Otezla, Evenity, Repatha |
| Idorsia Pharmaceuticals US INC | $241.56 | 2022-2023 | Quviviq |
| Pfizer INC. | $219.81 | 2021-2024 | |
| Lilly USA, LLC | $199.57 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.09 | 2021-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Biohaven Pharmaceutical Holding Company LTD. | $182.23 | 2022 | |
| Ardelyx, INC. | $158.75 | 2024 | Ibsrela |
| Mylan Specialty L.P. | $156.79 | 2021-2024 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $135.61 | 2024 | Aptima |
| Astellas Pharma US INC | $122.16 | 2023-2024 | Veozah |
| Verona Pharma, INC. | $120.99 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $109.46 | 2021 | |
| Electromed, INC. | $105.49 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.96 | 2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $65.25 | 2021 | |
| Ibsa Pharma INC. | $58.19 | 2022-2024 | Tirosint, Licart, Licart |
| Dexcom, INC. | $45.34 | 2022 | |
| Abbott Laboratories | $33.56 | 2023-2024 | Freestyle Libre, Freestyle Libre 3 |
| Antares Pharma, INC. | $30.01 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $25.64 | 2022 | |
| Grifols USA, LLC | $19.30 | 2024 | Prolastin-C Liquid |
| Organon LLC | $18.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.13 | 2022 | |
| United Therapeutics Corporation | $17.88 | 2022 | |
| Pulmonx Corporation | $16.82 | 2022 | |
| Insulet Corporation | $15.37 | 2021 | |
| Mckesson Medical-Surgical, INC. | $14.74 | 2023 | |
| Bard Access Systems, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.